The global protein expression technology market size is valued at USD 3.05 billion in 2025, up from USD 2.85 billion in 2024. Looking ahead, the market is expected to grow steadily and reach approximately USD 5.58 billion by 2034, expanding at a compound annual growth rate (CAGR) of 6.94% from 2025 to 2034.
Get a free sample of the Protein Expression Technology Market report to explore key insights and trends: https://www.towardshealthcare.com/download-sample/5806
The market is driven by the growing cases of chronic diseases, including cancer and diabetes, which propels demand for biologics, such as monoclonal antibodies, vaccines, and therapeutic enzymes that are produced using protein expression technologies. As well as major advancements in biotechnology and genetic engineering for large-scale manufacturing, with the development of cell-free and next-generation mammalian cell systems, and increasing R&D investments from various pharmaceutical and biopharmaceutical companies, are boosting the adoption of protein expression approaches.
The Protein Expression Technology Market: Highlights
- The protein expression technology market to cross USD 2.85 billion in 2024.
- Market projected at USD 5.58 billion by 2034.
- CAGR of 6.94% expected between 2025 to 2034.
- North America held a dominating revenue share by 45% of the global protein expression technology market in 2024.
- Asia Pacific is expected to grow at the fastest CAGR during 2025-2034.
- By expression system type, the bacterial expression systems segment led the market in 2024.
- By expression system type, the mammalian cell expression systems segment is expected to register the fastest expansion in the upcoming years.
- By product type, the recombinant proteins segment was dominant in the market in 2024.
- By product type, the antibodies segment is expected to show rapid expansion during the forecast period.
- By application type, the pharmaceuticals & biopharmaceuticals segment held a major revenue share of the market in 2024.
- By application type, the diagnostics segment is expected to be the fastest growing in the predicted timeframe.
- By end user, the biotechnology & pharmaceutical companies segment led the global protein expression technology market in 2024.
- By end user, the academic & research institutes segment is expected to grow fastest during 2025-2034.
Access the comprehensive databook featuring detailed market statistics, forecasts, and segment analysis: https://www.towardshealthcare.com/download-databook/5806
Market Overview: Insights & Potential 2025
Protein expression technology is one of the finest biotechnological processes that is used in the production of specific proteins for research or commercial application. Mainly, transcription of DNA into mRNA and then translation into functional proteins are involved. Because of major drivers, such as progressing demand for biologics, including monoclonal antibodies, vaccines, and therapeutic enzymes, for treating complex diseases like cancer, autoimmune diseases, and infectious diseases, are emphasizing on the latest developments. These developments are primarily contributing enhanced focus on optimization of expression effectiveness, outcomes, and quality by applying numerous host systems and techniques.
Key Metrics and Overview
|
Metric |
Details |
|
Market Size in 2025 |
USD 3.05 Billion |
|
Projected Market Size in 2034 |
USD 5.58 Billion |
|
CAGR (2025 - 2034) |
6.94% |
|
Leading Region |
North America Share by 45% |
|
Market Segmentation |
By Expression System, By Product Type, By Application, By End Use, By Region |
|
Top Key Players |
Thermo Fisher Scientific Inc., Merck KGaA (MilliporeSigma), Lonza Group AG, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Danaher Corporation, GE Healthcare (Cytiva), Promega Corporation, Qiagen N.V., Novoprotein Scientific Inc., Sino Biological Inc., GenScript Biotech Corporation, Proteintech Group, Takara Bio Inc., Jena Bioscience GmbH, Creative Biolabs, Abcam plc, Pierce Biotechnology (part of Thermo Fisher), LakePharma, Inc., Sutro Biopharma, Inc. |
Development of Recombinant Therapeutic
Proteins: Major Potential The global protein expression technology
market possesses many opportunities, mainly, the production of monoclonal
antibodies and other recombinant therapeutic proteins based on this kind of
technology. These emerging
recombinant therapeutic proteins are highly used in the treatment of
widespread diseases, including diabetes, growth hormone deficiency, hemophilia,
and cancer, as well as for immune modulation and as diagnostic tools. Besides
this, protein expression technology is also employed in the development of
enzymes for numerous industrial applications, like biofuel production and food
processing. Widespread Developments of Protein
Derivatives Company/Organizations Latest Developments Indian Council of Medical Research (ICMR) (July 2025) Invited the country’s vaccine manufacturers to align with it to
introduce and sell a malaria vaccine that its Regional Medical Research
Centre, Bhubaneshwar, has developed. RDP Pharma AG (July 2025) Partnered with the Experimental Drug Development Centre (EDDC) to
discover and evolve monovalent targeted protein degraders as potential new
therapeutic options for patients with chronic and debilitating autoimmune
diseases. BitBiome, Inc. (June 2025) Made a strategic partnership with a global contract manufacturing
organization (CMO) to allow large-scale manufacturing and supply of enzymes,
proteins, and other bio-based ingredients. Orion Partners (June 2025) Allied with Shilpa Biocare to launch virus-free recombinant human
albumin in Europe Arzeda (March 2023) Collaboration with Takeda focused on deploying AI-based protein
design to improve the properties of protein biologics.
You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com Complex Downstream Processing and Lack
of Expertise: Major Challenge Generally, the downstream processing
involved in the purification of recombinant proteins, particularly from complex
systems or those prone to aggregation, is mainly challenging in the global
protein expression technology market. Also, efficient use of protein expression
technologies needs specialized professionals, developing as limitation in the
developing market. The Protein Expression Technology
Market: Regional Analysis In 2024, North America was dominant in the
market share by 45%, due to crucial investments in research and development by
major pharmaceutical and biotechnology companies, resulting in wider focus on
protein expression technologies. Additionally, this region is increasingly
adopting recombinant DNA technologies and genetic engineering advancements,
which have allowed high efficiency and inexpensive protein manufacturing. U.S. & Canada Protein Expression
Technology Market Trends: Whereas, in the U.S., heavy demand for
biologics, which are reliant on protein expression systems by many
pharmaceutical and biotechnology industries, such as therapeutic proteins,
vaccines, and diagnostic tools, is boosting the overall protein expression
technology market growth. With immense breakthroughs in genetic engineering and
biotechnology, like CRISPR
and other gene editing technologies, being increasingly developed in
the US market. In Canada, the government is stepping up
with novel initiatives, such as the Canadian Institutes of Health Research
(CIHR) and the Strategic Innovation Fund, offering a vital expansion for R&D
in life sciences, accelerating innovation and growth in this protein
expression technology market. As well as a major surge in research activities,
particularly in synthetic
biology, personalized medicine, and RNA-based therapies, is fostering
technological breakthroughs with raised adoption of protein expression in
Canada. Get the latest insights on life science
industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership The Asia Pacific is Anticipated to
Register the Fastest Expansion During 2025-2034 Primarily, the protein expression
technology market, a rapid expansion in Asia Pacific is driven by accelerating
demand for biologics and biosimilars,
including monoclonal antibodies and vaccines. As well as in many ASAP
countries, such as China, India, and South Korea, which are assisting in
government funding and initiatives. These funds are further boosting research
and development
in the biopharmaceutical area with the expansion of protein expression
technology market. Besides this, various academic
institutions of ASAP are widely involved in proteomics biotechnology
research activities are also contributing to the overall market growth. China & India Protein Expression
Technology Market Trends: In Asia Pacific, China is a major hub for
the production of different biologics, especially monoclonal antibodies and antibody-drug
conjugates, recombinant protein production, biosimilars, and vaccines.
And these biologics are fueled by growing incidences of cancer, autoimmune
diseases, and chronic inflammatory diseases. Besides this, China is also
fostering the development of customized treatments by using protein expression
technology. On the other hand, India is facing
widespread growth in cancer, heart conditions, and genetic diseases, which are
fueling greater demand for protein-driven therapies and diagnostics. As well as
the Indian government is providing initiatives and investments for research in
proteomics and genomics
with increasing collaborations and partnerships among pharmaceutical
companies and academic institutions. The Protein Expression Technology
Market: Segmentation Analysis By Expression System Type Analysis The bacterial expression systems segment
held a major revenue share of the market in 2024. Majorly involved factors,
including especially E. coli, enable affordable culture and faster protein
production is developing as a popular choice for research and industrial
applications. Also, this segment has crucial importance in various industrial
productions, such as enzyme production and biofuel development. Although the mammalian cell expression
systems segment will expand rapidly, with significant
innovations in cell line development, like the use of CHO (Chinese
hamster ovary) and HEK293 (Human embryonic kidney) cells. These innovations
assist in boosting protein expression output and quality. Moreover, this
segment is widely used in the production of complex proteins like antibodies,
vaccines, and therapeutic proteins. Elevate your
healthcare strategy with Towards Healthcare. Enhance efficiency and drive
better outcomes schedule a call today: https://www.towardshealthcare.com/schedule-meeting By Product Type Analysis In 2024, the recombinant proteins segment
led the protein expression technology market. The segment is driven by its
broad applications in diagnostic assays, including immunoassays and vaccine
development, which is a necessary tool in disease diagnosis and monitoring. Furthermore,
these proteins are important for assessing protein-protein interactions, drug
discovery and basic research in various biological processes. However, the antibodies segment is
estimated to grow at the fastest CAGR, with its several uses in research
activities, like as Western blotting, ELISA, and immunohistochemistry to study
protein expression, function, and disease mechanisms. Although growing
cases of chronic diseases, including cancer and autoimmune disorders, are
propelling the need for more effective protein-based therapies, like
antibodies. By Application Type Analysis The pharmaceuticals &
biopharmaceuticals segment was dominant in the protein expression technology market
in 2024. Mainly, the segment is fueled by broad applications of protein
expression in diagnostics, industrial biotechnology, and research with new
opportunities, as well as raised demand for these technologies in drug
development and research. These novel drugs are greatly employed in addressing
healthcare issues, like cancer, genetic conditions, and other severe diseases. And, the diagnostics segment is anticipated
to expand rapidly, with innovations in expression systems, including cell-free
and plant-based systems, offering robust and inexpensive ways to produce
diagnostic proteins. Moreover, advances in protein purification approaches
boost the yield and purity of diagnostic proteins, resulting in more sensitive
and reliable diagnostic assays. Also, the microfluidic
devices are widely used in protein profiling for diagnostics,
especially in areas like cancer research, enabling opportunities for further
development and refinement of diagnostic tools. By End user Analysis The biotechnology & pharmaceutical
companies segment dominated the global protein expression technology market in
2024. Significant contribution of these companies in R&D to evolve novel protein-based
therapies, with rising approval and adoption of biosimilars, is impelling
demand for protein expression with enhanced protein production systems.
Large-scale production of monoclonal antibodies, vaccines, and therapeutic
enzymes is highly impacting the segment’s expansion. On the other hand, the academic &
research institutes segment will register the fastest growth, with increased
investments by government and non-government organizations in protein research,
which is highly influencing the market expansion. Besides this, novel
developments, such as cell-free
protein expression systems, gene editing tools, and AI-driven protein
design, are supporting in enhancement of protein production efficiency and
therapeutic accuracy is assisting researchers. Protein Expression Technology Market
Companies: What are the Major Developments in the Protein Expression Technology Market? Protein Expression Technology Market:
Segmentation By Expression System By Product Type By Application By End Use By Region Access the full ready report for
in-depth market intelligence, competitive landscape, and strategic
recommendations: https://www.towardshealthcare.com/price/5806 You can place an order or ask any
questions, please feel free to contact us at sales@towardshealthcare.com Gain access to the
latest insights and statistics in the healthcare industry by subscribing to our
Annual Membership. Stay updated on healthcare industry segmentation with
detailed reports, market trends, and expert analysis tailored to your needs.
Stay ahead of the curve with valuable resources and strategic recommendations.
Join today to unlock a wealth of knowledge and opportunities in the dynamic
world of healthcare: Get a Subscription About Us Towards Healthcare is a leading global provider of technological solutions, clinical
research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we
build strategic partnerships that generate actionable insights and
transformative breakthroughs. As a global strategy consulting firm, we empower
life science leaders to gain a competitive edge, drive research excellence, and
accelerate sustainable growth. Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards
Chemical and Materials | Towards Consumer
Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram Global Protein Market Segments – Growth Overview
(2024–2034) The global protein-related healthcare and
biotech sectors are experiencing rapid expansion across various niche markets.
Below is a breakdown of the key segments and their projected growth: Host Cell Protein Testing Market Proteinase K Market Protein Therapeutics Market Protein Engineering Market PEGylated Proteins Market Research Grade Proteins Market G-Protein Coupled Receptors (GPCRs)
Market C-Reactive Protein (CRP) Testing Market Plasma Protein Products Market Recombinant Lysyl Endopeptidase Market Recombinant Human Hair Keratin Protein
Market Protein Labeling Market
The host
cell protein testing market is valued at USD 2.37 billion in 2024 and
is expected to reach USD 5.19 billion by 2034, growing at a CAGR of 8.17%. This
growth is driven by increased biopharmaceutical production and the need for
stringent impurity testing.
The proteinase
K market is estimated at USD 4.82 billion in 2024 and projected to rise
to USD 10.93 billion by 2034, registering a CAGR of 8.54%. Demand is rising due
to its broad applications in DNA/RNA extraction and diagnostic kits.
The protein
therapeutics market is one of the largest and fastest-growing segments,
expected to expand from USD 375.3 billion in 2024 to USD 740.07 billion by
2034, at a CAGR of 7.08%. The rise is fueled by biologics and advanced
treatment approaches in chronic diseases.
The protein
engineering market is forecasted to grow from USD 3.08 billion in 2024
to USD 13.84 billion by 2034, with a high CAGR of 16.27%, driven by
breakthroughs in synthetic biology, enzyme optimization, and drug development.
The PEGylated
proteins market is anticipated to grow from USD 1.63 billion in 2024 to
around USD 4.95 billion by 2034, at a CAGR of 11.74%, as PEGylation continues
to improve drug delivery and half-life of protein-based drugs.
The research
grade proteins market is projected to expand from USD 1.13 billion in
2024 to USD 4.81 billion by 2034, growing at a CAGR of 15.57%. This is driven
by increasing investments in life sciences R&D and the rising need for
high-purity proteins in laboratories.
The G-protein
coupled receptors market is expected to grow from USD 3.86 billion in
2024 to USD 6.37 billion by 2034, at a steady CAGR of 5.14%, supported by its
central role in drug discovery and signal transduction research.
The C-reactive
protein testing market is showing slow yet stable growth, rising from
USD 5.58 billion in 2024 to USD 5.75 billion by 2034, with a CAGR of just 0.3%,
indicating market saturation in certain regions.
The plasma
protein products market was valued at USD 32.8 billion in 2023 and is
projected to grow to USD 72.9 billion by 2034, expanding at a CAGR of 7.53%.
This is due to increased use in immunology, hemophilia, and critical care
applications.
The recombinant
lysyl endopeptidase market is projected to grow from USD 38 million in
2023 to USD 67.06 million by 2034, with a CAGR of 5.3%, driven by applications
in mass spectrometry and protein structure analysis.
The recombinant
human hair keratin protein market is poised for significant growth
between 2024 and 2034, with revenues projected to climb substantially due to
increased adoption in wound care, cosmetics, and regenerative medicine.
The protein
labeling market is set to rise from USD 2.89 billion in 2025 to USD
6.02 billion by 2034, growing at a CAGR of 8.48%, fueled by its vital role in
proteomics, biomarker research, and targeted drug discovery.
